Early Bird Pricing Now Available - Book Now.
More informationJoin the community - networking, discussion and more. Open to all.
More informationCould you write an interesting article for the RQA community?
More informationPlease select your desired format:
Price: USD ($) 11.00
Price: USD ($) 0.00
Please note: payment is required before the ebooklet is sent via email. However if you need earlier access please contact publications@therqa.com.
VAT on Electronic Books is chargeable in the UK and EU. Please see the 'Booklet Terms and Conditions' for further details.
This second revision of the Pharmacovigilance Auditing booklet is intended to support auditors in the effective conduct of audits of the PV system by providing guidance in:
ʶ Directing audit focus to the higher risk areas of PV systems and discrete PV sub-systems to assist auditors with planning risk-based audits
ʶ The types of documentation which may be relevant for review
ʶ Additional hints and tips, and points for consideration, to help ensure audits are efficient and effective.
The booklet is considered fairly comprehensive, capturing activities managed by central functions and those that may be managed by an affiliate company. However, it is acknowledged that it is not all inclusive, and there may be additional processes or functional groups that could be included within the scope of an audit. It is envisaged that an auditor may select areas from this booklet of relevance to the system they wish to audit.
While the focus of this booklet is the EU legislative requirements, the reality with regards to PV is that multinational companies operate in a global environment. Therefore, while national regulation must, of course, be considered both within the EU and ex-EU, it is anticipated that this guide may be applied as a basis for PV audit across geographical boundaries.
For those new to PV auditing, the content of this publication may appear a little overwhelming at first. We hope it will provide some guidance as to where to start, what to include and where key areas of focus could be. Good luck!
Lauren Ewen (team lead), Pam Bones, Mark Parker, Lindsay Watt, Louise Alford, Sandra Dunlavy, Kim Palmer, Deepti Naik.
April 2022
Comparison of Pharmacovigilance Regulations in Europe and Japan
Management of the Training and Competency of Personnel in GxP and Research Environments
Pharmacovigilance Agreements (PVAs): Guidance on the Quality Oversight and Operational Aspects
P11 A Systems Approach to Good Pharmacovigilance Practice
P35 Practical Pharmacovigilance Auditing
P36 Practical Approach to Good Pharmacovigilance Regulatory Inspections
RP35 Practical Pharmacovigilance Auditing REMOTE LEARNING